Cumberland reports positive early-stage data for cancer metastasis drug

Cumberland Pharmaceuticals (NASDAQ:CPIX) and Vanderbilt Health announced that a Phase 2a clinical trial evaluating the investigational drug ifetroban successfully met its primary endpoint, demonstrating safety and tolerability in patients with high-risk solid tumors.

The randomized, double-blind, placebo-controlled pilot study evaluated 29 participants diagnosed with various types of aggressive cancers, including breast, lung, pancreatic, soft tissue, bladder, and renal tumors.

The enrolled cohort consisted of patients who had completed standard therapies and surgical procedures but remained at a high baseline risk for early metastatic recurrence.

The study met its primary objective, showing a safety profile where treatment-related adverse event rates were similar between the ifetroban and placebo arms, with no treatment-related serious adverse events recorded.

Although the exploratory study was primarily designed to analyze safety parameters and was not fully powered for statistical efficacy, the tracking of pre-specified secondary endpoints revealed strong anti-metastatic signals.

At the 12-month post-therapy evaluation threshold, 17% of patients in the ifetroban treatment group experienced distant metastatic recurrence, compared to 50% of participants in the placebo group.

Furthermore, three deaths due to distant metastatic disease were recorded within the placebo arm, whereas zero deaths occurred among patients treated with ifetroban.

Ifetroban is an oral, small-molecule thromboxane A2 receptor antagonist developed to block the pathways that facilitate platelet-tumor cell interactions, which are believed to contribute directly to cellular migration and cancer metastasis.

Management noted that the positive early data support the continued clinical development of ifetroban as a potential preventative treatment to navigate post-therapeutic observation windows.

Beyond oncology, Cumberland is actively advancing the compound across separate Phase 2 pipelines targeting rare diseases, including Duchenne muscular dystrophy-associated cardiomyopathy, systemic sclerosis, and idiopathic pulmonary fibrosis.